WO2022239556A1 - 幹細胞用冷蔵保存液及び保存方法 - Google Patents
幹細胞用冷蔵保存液及び保存方法 Download PDFInfo
- Publication number
- WO2022239556A1 WO2022239556A1 PCT/JP2022/015708 JP2022015708W WO2022239556A1 WO 2022239556 A1 WO2022239556 A1 WO 2022239556A1 JP 2022015708 W JP2022015708 W JP 2022015708W WO 2022239556 A1 WO2022239556 A1 WO 2022239556A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- solution
- days
- refrigerated
- ionic species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/54—Mechanical aspects of preservation of animal cells or human cells; Apparatus or containers therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/52—Chemical aspects of preservation of animal cells or human cells
- C12N5/522—Preservation media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/52—Chemical aspects of preservation of animal cells or human cells
- C12N5/522—Preservation media
- C12N5/525—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/52—Chemical aspects of preservation of animal cells or human cells
- C12N5/522—Preservation media
- C12N5/526—Physiologically active agents, e.g. antioxidants or nutrients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/56—Physical preservation processes for animal cells or human cells
- C12N5/562—Temperature processes, e.g. following predefined temperature changes over time
Definitions
- the present invention relates to a preservation solution and preservation method for preserving cells, tissues, organoids, organs, etc. in a non-frozen state.
- it relates to refrigerated storage solutions and storage methods for storage at temperatures below room temperature, such as 2-15°C, 2-10°C, 2-8°C or 2-6°C.
- refrigerated storage solution and storage method for preserving pluripotent cells such as human iPS cells and other stem cells, or derivatives such as organoids obtained therefrom, early embryos, etc. by suspending or immersing them. refrigerated storage solution and storage method.
- Cryopreservation of human iPS cells and ES cells has many problems, such as the low survival rate after preservation with slow cryopreservation, and the cytotoxicity and differentiation-inducing properties of DMSO, a cryoresistant material used for cryopreservation.
- DMSO a cryoresistant material used for cryopreservation.
- Non-freezing cryopreservation of cells is a very attractive technique for short-term (e.g., 1 day to 2 weeks) to medium-term (e.g., half a month to 3 months) storage methods, as well as storage of differentiation-induced cells and storage of organoids.
- UW solution is widely used for refrigerated storage of organs used for transplantation, such as liver and kidney, and is virtually the gold standard (optimal standard).
- the UW solution developed in the 1980s, consists of an intracellular low Na ion, high K ion salt composition solution containing lactobionate, raffinose, glutathione, and hydroxyethyl starch ( Hydroxy-ethyl Starch), etc., has a relatively simple composition.
- the salt composition should be intermediate between the intracellular salt composition represented by the UW solution and the high Na ion low K ion extracellular salt composition of a normal medium. hypothesized to be important.
- the addition of macromolecules such as protein is more important than organ preservation, we developed an intermediate preservation solution between UW solution and cell culture solution.
- HTS FRS Hypothermosol (registered trademark) FRS; BioLife Solutions. It has been reported that this HTS FRS is capable of cryopreserving human dermal fibroblasts and smooth muscle cells for 3 to 5 days, but there is no report on cryopreservation of pluripotent cells such as human iPS cells.
- MEM-alpha Minimum Essential Medium Eagle (MEM) Alpha Modification
- MEM-alpha is based on MEM media containing non-essential amino acids, sodium pyruvate, lipoic acid, biotin and vitamin B12. It has been known that by using such an improved refrigerated preservation solution, human iPS cells and the like can be refrigerated for several days or longer and their viability can be maintained to some extent.
- the inventors used the above-mentioned improved refrigerated preservation solution and attempted to insert an awakening period during the period of refrigerated preservation. That is, in hibernation, for example, when hibernating at hypothermia from around 20°C to less than 10°C, short awakening periods are repeated at certain intervals. Tried to insert a short period of time to return to conditions or near conditions. By confirming the effect of this through experiments, the invention was completed.
- refrigerated storage is performed as described in (i) to (iii) below.
- Arousal periods are interspersed at regular or non-regular intervals during refrigerated storage over the 20-day period.
- the wakefulness period can be set as follows.
- Length of each awakening period 0.5 to 10 hours, especially 1 to 8 hours.
- Temperature in each waking period 37°C or lower and 30°C or higher, 32°C or higher, 33°C or higher, 34°C or higher, or 35°C or higher.
- Interval between wakefulness periods 2-8 days, especially 2-5 days, eg 3-4 days.
- refrigerated storage for example at 2-10° C.
- refrigerated storage is performed by standing in a refrigerator or cold room, and the arousal period insert is transferred to a normal incubator and under normal cell culture conditions ( Typically, this can be achieved by placing at 37° C., 5% CO 2 ).
- the arousal period should be inserted at regular intervals for a certain length, for example, every 3 days, 2 days, or 4 days, for a certain period of time set in the range of 1 to 6 hours. can be done.
- MEM (Eagle's minimal essential medium) medium such as MEM-alpha contains the following components (1) to (4).
- amino acids L-arginine, L-cystine, L-glutamine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine, L -valine
- salts calcium chloride, potassium chloride, magnesium sulfate, sodium chloride, sodium dihydrogen phosphate
- D-glucose and (4) vitamins (folic acid, nicotinamide (niacinamide), riboflavin, B12, choline, inositol, pantothenic acid, pyridoxal phosphate, thiamine).
- the UW solution is a Ca 2+ -free fluid with an intracellular composition. It contains adenosine as a precursor for relaxation and ATP, glutathione and allopurinol for antioxidants, and phosphate buffer as a buffer component.
- a refrigerating storage solution has the following features a1-a6 or a1-a9. a1.
- the content of potassium ion species is 20-90 mmoL/L or 30-80 mmoL/L, and the content of sodium ion species is 20-90 mmoL/L or 30-80 mmoL/L.
- the amount of sodium ionic species is 0.5-1.5, 0.5-1.3, or 0.6-1.2 in the molar ratio of ion base to potassium ionic species (Na + /K + ratio).
- a3. Contains Trolox or an analog thereof at a concentration of 0.5-10 mM, 1-8 mM or 2-7 mM. a4.
- the total content of non-essential amino acids is preferably 100-500 mg/L, especially 50-200 mg/L or 80-150 mg/L. a7.
- the content of magnesium ion species is 2-8 mmoL/L, 2-5 mmoL/L or 2-4 mmoL/L, and the content of calcium is 0.2-1.5 mmoL/L, 0.2-1 mmoL. /L or 0.3-0.8mmoL/L. a8.
- a refrigerating storage solution contains (i) 30 to 100 mmoL/L (or 10 to 40 g/L) of lactobionic acid or its salt (Lactobionic acid or lactobionate) in terms of lactone, (ii) raffinose hydrate 10-30 mmoL/L (or 5-20 g/L), (iii) allopurinol 0.3-1 mmoL/L (or 0.05-0.1 g/L), (iv) glutathione (total glutathione) 1-3 mmoL/L, (v) adenosine 2-10 mmoL/L (or 0.3-0.9 g/L), and (vi) lipoic acid 0.05-1 ⁇ moL/L (or 0.03-0.2 mg/L), (vii) sodium pyruvate 0.1-1 mmoL /L (or 10-100 mg/L), (viii) glucose 0.5-10 mmoL/L (or 100-
- This refrigerated storage solution preferably contains 20-50 g/L of (xv) hydroxyethyl starch. It also preferably contains (xvi) 4-40 mg/L of ribonucleosides and/or (xvii) 4-40 mg/L of deoxyribonucleosides. It also preferably contains 10-25 mmoL/L of potassium dihydrogen phosphate and sodium dihydrogen phosphate.
- FIG. 10 is a graph showing changes in proliferation rate over the storage period when the same improved refrigerated storage solution as used in the embodiment of the present application is used and continuously refrigerated at 4°C.
- FIG. 4 is a schematic diagram showing the main points of refrigerated storage with arousal insertion (lower) and continuous refrigerated storage without awake insertion (upper) and the procedure for evaluation according to the embodiment of the present application.
- 10 is a bar graph showing the effect of the length of the wakefulness period when the wakefulness period is inserted after 3 days of refrigerated storage for 6 days. Fluorescent micrographs showing dead cells immediately after the end of cold storage and after 1 hour of recovery culture during the cold storage experiment that gave the results of FIG. 3 were converted to grayscale.
- FIG. 1 is a graph summarizing the results of 12 days of refrigeration using two improved refrigeration solutions and two conventional conventional refrigeration solutions. Using each refrigerated preservation solution, the case where the insertion of the waking period for 3 hours every 3 days (Hib) and the case where it was not performed are collectively shown.
- FIG. 4 is a bar graph showing the effect of waking period insertion during refrigerated storage of mouse embryos.
- FIG. 1 is a graph summarizing the results of refrigerating mouse embryos in an improved refrigerating solution for 12 days. The case where the insertion of the waking period for 3 hours every 3 days (Hib) and the case where it was not performed are collectively shown.
- the refrigerating storage solution used in a preferred embodiment of the present invention is a physiological buffer containing the following (i) to (vi), and has a pH of 7 to 7.5.
- Lipoic acid 0.05-1 ⁇ moL/L, 0.1-0.5 ⁇ moL/L or 0.2-0.4 ⁇ moL/L, or 0.03-0.2 mg/L or 0.05-0.1 mg/L.
- sodium pyruvate 0.1-1 mmoL/L, 0.1-0.7 mmoL/L or 0.2-0.5 mmoL/L, or 10-100 mg/L or 20-50 mg/L;
- antioxidant vitamins or their water-soluble analogues/derivatives (both of which can be in the form of salts.
- ix-1 of the following two types can be omitted.
- ix-1 Ascorbic acid 0.03-0.3 mmoL/L, 0.05-0.2 mmoL/L or 0.05-0.15 mmoL/L, or 5-20 mg/L or 10-15 mg/L.
- ix-2 0.5-10 mM, 1-8 mM or 2-7 mM of vitamin E, Trolox or other water-soluble vitamin E analogs and derivatives.
- (x) Adenine or a salt or derivative thereof 0.1-6 mM, 0.1-5 mM, 0.1-4.5 mM, 0.1-4.2 mM or 2-5 mM. Optionally 0.1-0.3 mM or 0.05-0.2 mM.
- Folic acid 0.2-2 ⁇ moL/L, 0.3-1 ⁇ moL/L or 0.5-0.9 ⁇ moL/L, or 0.1-1 mg/L or 0.2-0.5 mg/L. xi-4.
- Niacinamide 0.5-8 ⁇ moL/L, 1-6 ⁇ moL/L or 1-4 ⁇ moL/L, or 0.03-0.2 mg/L or 0.05-0.1 mg/L. xi-5.
- Riboflavin 0.03-0.3 ⁇ moL/L, 0.04-0.2 ⁇ moL/L or 0.05-0.15 ⁇ moL/L, or 0.03-0.2 mg/L or 0.05-0.1 mg/L. xi-6.
- (xii) Total essential amino acids 50-200 mg/L or 80-150 mg/L.
- the amount of each component is in the range of A/3 to 3A ( That is, it can be appropriately set within the range of 1/3 to 3 times the value in "HTM-alpha"), or within the range of A/2 to 2A.
- xii-1 Isoleucine xii-2. Leucine xii-3. Lysine xii-4. Methionine xii-5. Phenylalanine xii-6. Threonine xii-7. Tryptophan xii-8. Valine xii-9. Histidine
- (xiii) Total non-essential amino acids 100-500 mg/L or 150-400 mg/L. (Either of these can take the form of a salt. In addition, among the following 10 types, 1 to 5 types, 1 to 4 types, or 1 to 3 types can be omitted.) Asparagine xiii-5. Aspartic acid xiii-6. Cysteine xiii-7. Cystine xiii-8. Glutamic acid xiii-9. Proline
- the refrigerated storage solution preferably contains (xvi) below. (xvi) 10-80 g/L, 20-50 g/L or 20-40 g/L of hydroxyethyl starch.
- This refrigerated storage solution preferably contains at least one of (xvii) and (xviii) below.
- This refrigerated storage solution preferably contains the following (xix) to (xx).
- the sodium ionic species has a molar ratio (Na/K ion ratio) of, for example, 0.7 to 1.3 times, 0.8 to 1.2 times, or 0.9 to 1.1 times that of potassium ionic species. can be double. Also, in another preferred embodiment, the sodium ionic species can be at a molar ratio of, for example, 0.5-1.5 times, 0.5-1.3 times, or 0.6-1.2 times the potassium ionic species.
- the refrigerated storage solution used in preferred embodiments of the present invention contains Trolox or other water-soluble vitamin analogs as described above at 0.1 mM or greater, 0.3 mM or greater, 0.5 mM or greater, 1 mM or greater, 2 mM or greater, 3 mM or more, 4 mM or more, or 5 mM or more, including concentrations of 10 mM or less, 8 mM or less, or 6 mM or less.
- the refrigerated storage solution used in a preferred embodiment of the present invention contains adenine or a salt thereof at 0.1 mM or more, 0.3 mM or more, 0.5 mM or more, 1 mM or more, 2 mM or more, 3 mM or more. , at a concentration of 8 mM or less, 6 mM or less, 5 mM or less or 4 mM or less, such as a concentration of 0.1-4.2 mM or 1-4.2 mM.
- the addition of adenine is considered to have a remarkable effect in preserving embryos and organoids, in which cells adhere to each other to form a three-dimensional mass.
- the refrigerated storage solution used in preferred embodiments of the present invention further comprises L-alanyl-L-glutamine, or other dipeptide substitutes, or salts thereof, at concentrations of 1-6 mM, 2-5 mM, or 3-5 mM. include.
- the refrigerated storage solution used in a preferred embodiment of the present invention is a UW solution whose composition is shown in Table 1 and a MEM alpha medium whose composition is shown in Table 2.
- the UW solution is 1 to 3 times the MEM alpha medium, preferably It is obtained by mixing at a volume ratio of 1.5 to 2.5 times, more preferably 1.8 to 2.2 times.
- the composition of Tables 1 and 2 and the content of each component obtained from this mixing ratio are within the range of ⁇ 50%, within the range of ⁇ 40%, within the range of ⁇ 30%, or within the range of ⁇ 20% Within the range, it is possible to increase or decrease as appropriate.
- some of the components particularly those listed in Table 2, some of the non-essential amino acids (eg 1-5), some of the nucleosides (eg 1-5) , some of the vitamins (eg 1-5), some of the inorganic salts (eg 1-3), and phenol red can be omitted.
- a method of cold storage according to a preferred embodiment of the present invention is to store pluripotent cells at 1 ⁇ 10 3 cells/mL to 1 ⁇ 10 9 cells/mL in any of the cold storage solutions described above, or The cells are dispersed in a single-cell state so as to be 1 ⁇ 10 4 cells/mL to 1 ⁇ 10 8 cells/mL, and stored in a refrigerator for, for example, 1 to 10 days or 1 to 7 days.
- a method of refrigerated storage comprises adding 1 ⁇ 10 3 cells/cm 2 to 1 ⁇ 10 pluripotent cells in a culture vessel containing any of the above refrigerated preservation solutions. 9 cells/cm 2 or 1 ⁇ 10 4 cells/cm 2 to 1 ⁇ 10 8 cells/cm 2 and cultured for, for example, 2 to 6 days, and then, for example, 1 to 10 days or 1 to 7 days. Keep refrigerated.
- the cells can be kept adhered to the medium, that is, in a normal culture state.
- the cells can remain attached to the culture medium over a period of time.
- the pluripotent cells or stem cells to be cold-preserved are, for example, pluripotent cells such as ES cells and induced pluripotent stem cells such as iPS cells, or hematopoietic stem cells, neural stem cells, liver These include stem cells, skin stem cells, and germ stem cells.
- pluripotent cells to be stored under cold storage can be derived from humans or mammals such as primates, mice, and guinea pigs.
- the subject of cold storage can be human or animal embryos, particularly embryos of livestock animals such as cows, horses, pigs, and goats.
- StemFit registered trademark
- AK02N medium containing 10 ⁇ M Y27362 (Fujifilm Wako Pure Chemical Industries, Ltd.) as a ROCK inhibitor
- iMatrix-511 MATRIXOME, Inc.
- culture was performed in a 37° C. incubator (5% CO 2 ) unless otherwise specified.
- Refrigerated storage solution Two or three types of refrigerated storage solutions were prepared as follows. For convenience, we will call them HTM-alpha, and HTMX2C13 and HTMM19, respectively. In each case, Trolox was added to 5 mM, and GlutaMAX (registered trademark, GIBCO) was added to a 5-fold concentration (x5; 10 mM).
- - HTM-alpha UW solution + MEM-alpha (12571-MEM alpha, nucleosides, Thermo Fisher Scientific), mixing volume ratio: 2/1.
- HTMx2c13 Modification of HTM-alpha solution. Mannitol 90mM, PVA 0.25% was added instead of hydroxyethyl starch. That is, a modified UW solution was prepared by omitting hydroxyethyl starch and containing 90 mM mannitol and 0.25% polyvinyl alcohol from the composition of the UW solution shown in Table 1 below. MEM alpha) was mixed at a volume ratio of 2/1 and used.
- the polyvinyl alcohol (PVA) used here is Merck #363146, which has a degree of saponification of 99%, a weight average molecular weight Mw of 85,000 to 124,000, and a rotational viscosity of 4% aqueous solution at 20°C of 28 to 32 mPa/sec. (28-32 cP, 4% in H2O (20°C) (lit.)).
- ⁇ HTMM19 Modification of HTM-alpha solution.
- a MEM-alpha solution with modified amino acid composition and vitamin composition was prepared, and the UW solution and this modified MEM-alpha solution were mixed at a volume ratio of 2:1.
- the amino acid composition and vitamin composition of the modified MEM-alpha solution used here are shown in Tables 4 and 5 below, respectively.
- HTMa + 10% KSR and HTMa + PVA99_0.2% were also used.
- HTMa + 10% KSR 10% by weight of KnockOut TM Serum Replacement (KSR) added to the above HTM-alpha.
- KnockOut TM Serum Replacement (KSR) used here is a serum-free supplement and serum replacement for culturing human and mouse pluripotent stem cells.
- ⁇ HTMa+PVA99_0.2% 0.2% by weight of polyvinyl alcohol (PVA) is added to the above HTM-alpha.
- PVA polyvinyl alcohol
- the polyvinyl alcohol used here is the same as that used in HTMx2c13 above.
- Non-Patent Document 3 the composition of the UW liquid (BELZER UW (registered trademark) COLD STORAGE SOLUTION) is as shown in the table below.
- the MEM alpha medium (12571 - MEM alpha, nucleosides, Thermo Fisher Scientific) used in "HTM-alpha” has the following composition (https://www.thermofisher.com/jp /en/home/technical-resources/media-formulation.94.html).
- GlutaMAX (registered trademark, GIBCO) added to "HTM-alpha" is a 200 mM solution (“GlutaMAX TM I (100 ⁇ )”). This was diluted to 1/20 and added to "HTM-alpha” so as to be 10 mM (5 ⁇ ).
- Table 3 summarizes sodium ions, potassium ions, and their molar ratios for the UW solution, HTM-alpha, HTMX2C13, and HTS-FRS.
- the ion concentration in StemFit (registered trademark) AK02N is the same as that in MEM-alpha. With reference to the experimental results to be described later, it was thought that the molar ratio of Na + /K + should be around 1 or slightly smaller.
- proteins, peptides, and growth factors are contained in StemFit (registered trademark) AK02N, but not in MEM-alpha. Therefore, it is not included in HTM-alpha.
- the medium was replaced with each of the refrigerated storage solutions described in "2.” above, and stored at 4°C for 3 days, 6 days, or 9 days. That is, the cells aggregated and adhered to each other, and were stored in a refrigerator for a predetermined period in a state of adhering to the culture vessel.
- FIG. 2 schematically shows the insertion of arousal according to the present invention and the subsequent cell proliferation assay procedure.
- FIG. 1 shows the results when no arousal is inserted, as shown in the upper part of FIG.
- Fig. 3 shows the effect of inserting an awakening period as shown in the lower part of Fig. 2. That is, after 3 days (72 hours) from the start of cold storage, the cells were transferred to a 37° C. incubator and placed under culture conditions for 1 hour, 3 hours or 6 hours. Then, the cells were returned to the 4° C. refrigerator again, and after another 2.75 days (66 hours), the cells were cultured for one day and then subjected to a cell proliferation assay.
- the cell proliferation rate was significantly increased by inserting an awake period. Increasing the wakefulness period from 1 hour to 3 hours produced a marked increase, but increasing from 3 hours to 6 hours appeared to increase somewhat more, albeit not significantly. I didn't.
- FIG. 4 shows, in grayscale, fluorescent micrographs showing dead cells immediately after the refrigerated storage in “5.” above and after the one-day recovery culture above, regarding the effect of hibernation-type awakening insertion. Specifically, the cells were stained with Live or Dead TM Dead Cell Staining Kit from Takara Bio Inc., and the stained portions are shown in white.
- FIG. 4 shows the state of the cells before refrigerated storage after 1 day of recovery culture similar to the above, but of course, no significant cell death was observed.
- the lower left part of FIG. 4 shows the state of continuous refrigeration storage for 6 days without arousal insertion. The area of dead cells was significantly greater after 1 day of recovery culture than immediately after cold storage. On the other hand, when the 6-hour awake period shown in the lower right of FIG. A decrease in cell death was more pronounced.
- HTM-alpha and HTMx2c13 improved refrigerated storage solutions
- HTM-a_Hib and HTMx2c13_Hib showed a cell growth rate of about 60% or more than that in the unpreserved case.
- HTM-a_Hib and HTMx2c13_Hib showed a cell growth rate of about 60% or more than that in the unpreserved case.
- the cell growth rate after 6 days and 9 days was significantly reduced, as shown in the lower right half of FIG. was impractical.
- almost no cell proliferation was observed after 12 days.
- FIG. 6 shows the rate of embryos that escaped from the zona pellucida and the development rate of embryos during the two-day culture period after culturing for two more days.
- FIG. 6 also shows the results of similarly culturing an unpreserved control (Fresh_Control) that was not refrigerated.
- Hed + Hing indicates the total of embryos that have escaped from the zona pellucida and embryos that are in the process of escape.
- Exp means expanded blastocyst stage embryos. Expanded blastocysts are in a state just before they become escaped blastocysts and have a high probability of normal embryo development, and were added to the embryo development rate. Although data are not shown here, the UW solution and HTS FRS showed significantly low escape rates of 29.4% and 15.0%, respectively, in the 3-day storage section.
- Fig. 7 shows the transparent object escape rate (black background) shown in Fig. 6 in the form of a line graph.
- the error bars in the line graph indicate standard deviations based on 2 to 6 experiments.
- Tables 4 and 5 show the amino acid composition and vitamin composition of the modified MEM-alpha solution used to obtain the refrigerated storage solution HTMM19 (2:1 mixture of UW solution and modified MEM-alpha solution) used here. show. As is known from comparison with the composition of the MEM alpha medium in Table 3, some amino acids and vitamins are omitted in the modified MEM-alpha solution.
- Refrigerated storage technology for iPS cells has a limited storage period compared to cryopreservation, but it can be stored in a cultured state (adherent), and storage and transportation of differentiation-induced organoids that cannot be frozen. , or on-demand cell supply in drug discovery research. Therefore, this technology that enables preservation of human iPS cells is very important.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020237038212A KR102998705B1 (ko) | 2021-05-11 | 2022-03-29 | 줄기세포용 냉장 보존액 및 보존 방법 |
| US18/290,016 US20250230417A1 (en) | 2021-05-11 | 2022-03-29 | Non-freezing refrigerated storage liquid and storage method for stem cells |
| EP22807260.9A EP4338590A4 (en) | 2021-05-11 | 2022-03-29 | COLD STORAGE SOLUTION AND STORAGE METHOD FOR STEM CELLS |
| CN202280033722.XA CN117441013A (zh) | 2021-05-11 | 2022-03-29 | 干细胞用冷藏保存液以及保存方法 |
| JP2023520914A JPWO2022239556A1 (cg-RX-API-DMAC7.html) | 2021-05-11 | 2022-03-29 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-080546 | 2021-05-11 | ||
| JP2021080546 | 2021-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022239556A1 true WO2022239556A1 (ja) | 2022-11-17 |
Family
ID=84028242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2022/015708 Ceased WO2022239556A1 (ja) | 2021-05-11 | 2022-03-29 | 幹細胞用冷蔵保存液及び保存方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250230417A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4338590A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2022239556A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102998705B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN117441013A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022239556A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102870918B1 (ko) | 2024-01-23 | 2025-10-14 | 주식회사 이에이치엘바이오 | 소변 내 세포의 보존을 위한 소변 중화액 조성물 및 이를 이용한 소변 중화 처리방법 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012116823A (ja) * | 2010-12-03 | 2012-06-21 | Kyoto Univ | 生体組織保存溶液及びそれを用いる方法 |
| JP2013536804A (ja) * | 2010-09-01 | 2013-09-26 | オルガン・パフュージョン・プロプライエタリー・リミテッド | 灌流組成物 |
| WO2014030211A1 (ja) * | 2012-08-21 | 2014-02-27 | 全国農業協同組合連合会 | 哺乳動物の胚又は受精卵の非凍結低温保存方法 |
| CN106614524A (zh) * | 2016-11-26 | 2017-05-10 | 中国人民解放军第四军医大学 | 一种间充质干细胞的保存液以及保存方法 |
| CN108651442A (zh) * | 2018-05-17 | 2018-10-16 | 广东芙金干细胞再生医学有限公司 | 一种间充质干细胞4℃储存液 |
| WO2021090869A1 (ja) * | 2019-11-08 | 2021-05-14 | 株式会社バイオベルデ | 幹細胞用冷蔵保存液 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809101B1 (en) | 2004-11-12 | 2016-11-02 | Organoflush B.V. | Composition for cold preservation and perfusion of organs |
| PL3277083T3 (pl) | 2015-04-03 | 2025-05-26 | Vivalyx Gmbh | Zastosowanie kompozycji do prezerwacji narządów w celu prezerwacji narządu lub jego części |
| EP3772936A4 (en) * | 2018-04-09 | 2022-01-05 | CellResearch Corporation Pte. Ltd. | METHOD FOR TRANSPORTING MESENCHYMAL STEM CELLS BY A TRANSPORT SOLUTION AND METHOD FOR ADMINISTERING STEM CELLS TO WOUNDS |
| EP4040957A4 (en) * | 2019-10-08 | 2023-11-01 | CellResearch Corporation Pte. Ltd. | MESENCHYMAL STEM CELL STORAGE OR TRANSPORT FORMULATION AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| WO2022241417A1 (en) * | 2021-05-10 | 2022-11-17 | The General Hospital Corporation | Methods and compositions for extending organ and tissue preservation |
-
2022
- 2022-03-29 JP JP2023520914A patent/JPWO2022239556A1/ja active Pending
- 2022-03-29 WO PCT/JP2022/015708 patent/WO2022239556A1/ja not_active Ceased
- 2022-03-29 KR KR1020237038212A patent/KR102998705B1/ko active Active
- 2022-03-29 US US18/290,016 patent/US20250230417A1/en active Pending
- 2022-03-29 EP EP22807260.9A patent/EP4338590A4/en active Pending
- 2022-03-29 CN CN202280033722.XA patent/CN117441013A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013536804A (ja) * | 2010-09-01 | 2013-09-26 | オルガン・パフュージョン・プロプライエタリー・リミテッド | 灌流組成物 |
| JP2012116823A (ja) * | 2010-12-03 | 2012-06-21 | Kyoto Univ | 生体組織保存溶液及びそれを用いる方法 |
| WO2014030211A1 (ja) * | 2012-08-21 | 2014-02-27 | 全国農業協同組合連合会 | 哺乳動物の胚又は受精卵の非凍結低温保存方法 |
| CN106614524A (zh) * | 2016-11-26 | 2017-05-10 | 中国人民解放军第四军医大学 | 一种间充质干细胞的保存液以及保存方法 |
| CN108651442A (zh) * | 2018-05-17 | 2018-10-16 | 广东芙金干细胞再生医学有限公司 | 一种间充质干细胞4℃储存液 |
| WO2021090869A1 (ja) * | 2019-11-08 | 2021-05-14 | 株式会社バイオベルデ | 幹細胞用冷蔵保存液 |
Non-Patent Citations (6)
| Title |
|---|
| AIZAWA, AKIRA ET AL.: "3P-0445 Novel hypothermic preservation solution can effectively suppress hypothermal and oxidative stress of human iPSC", 41ST ANNUAL MEETING OF THE MOLECULAR BIOLOGY SOCIETY OF JAPAN; NOV. 28 - 30, 2018, MOLECULAR BIOLOGY SOCIETY OF JAPAN, JP, vol. 41, 9 November 2018 (2018-11-09) - 30 November 2018 (2018-11-30), JP, pages 3P - 0445, XP009535468 * |
| AKIRA AIZAWA: "The 18th Annual Meeting of the Japanese Society for Regeneration and Medical Care", 22 February 2018, BIOVERDE CO., LTD., article "P-01-015, Development of a new storage solution with low-temperature stress / oxidative stress protection effect for refrigerated storage of human iPS cells" |
| AKIRA AIZAWAMISA KIIWOOGI HYONSUONG-HYU HYON: "3P-0445, Low-temperature-stress and oxidation-stress protection effect by newly developed non-freezing low-temperature storage liquid for human iPS cells", 9 November 2018, BIOVERDE CO., LTD. 2 |
| CHEN GUOKAI, GULBRANSON DANIEL R, HOU ZHONGGANG, BOLIN JENNIFER M, RUOTTI VICTOR, PROBASCO MITCHELL D, SMUGA-OTTO KIMBERLY, HOWDEN: "Chemically defined conditions for human iPSC derivation and culture", NATURE METHODS, NATURE PUBLISHING GROUP US, NEW YORK, vol. 8, no. 5, 1 May 2011 (2011-05-01), New York, pages 424 - 429, XP055789009, ISSN: 1548-7091, DOI: 10.1038/nmeth.1593 * |
| COMPARE BELZER UWTM COLD STORAGE LIQUID TO VIASPAN, Retrieved from the Internet <URL:https://bridgetolife.com/compare-belzer-uw-cold-storage-solution-to-viaspan> |
| See also references of EP4338590A4 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102998705B1 (ko) | 2026-07-30 |
| EP4338590A4 (en) | 2025-04-30 |
| CN117441013A (zh) | 2024-01-23 |
| US20250230417A1 (en) | 2025-07-17 |
| KR20230165334A (ko) | 2023-12-05 |
| EP4338590A1 (en) | 2024-03-20 |
| JPWO2022239556A1 (cg-RX-API-DMAC7.html) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7636797B2 (ja) | 幹細胞用冷蔵保存液 | |
| TWI670371B (zh) | 用於細胞冷凍保存的組成物和方法 | |
| US8017311B2 (en) | Method for treatment of cellular materials with sugars prior to preservation | |
| US6140123A (en) | Method for conditioning and cryopreserving cells | |
| US6485959B1 (en) | Cell preconditioning and cryopresevation medium | |
| JP7038369B2 (ja) | ウシ生殖細胞の凍結保存用組成物及び凍結保存方法 | |
| CN119816201A (zh) | 在低温环境下保存细胞活力的组合物和方法 | |
| JP2006230396A (ja) | 細胞保存液 | |
| US20030049840A1 (en) | Cell preconditioning and cryopreservation medium | |
| EP4338590A1 (en) | Cold storage solution and storage method for stem cells | |
| KR102148998B1 (ko) | 간세포 및 캡슐화한 간세포 구상체의 동결 보존을 위한 동결보존용 무혈청 용액 및 이를 이용한 동결보존법 | |
| KR20150101498A (ko) | 아스타잔틴 또는 커큐민을 포함하는 돼지 정자 동결보존용 조성물 | |
| RU2450515C1 (ru) | Средство для консервации донорской роговицы | |
| JP4739420B2 (ja) | ヒト胚の体外受精及び培養用培養液及びヒト胚の体外受精及び培養方法 | |
| HK40102872A (en) | Cold storage solution and storage method for stem cells | |
| US20080145930A1 (en) | Methods and compositions for reanimating cryopreserved oocytes | |
| US20080213887A1 (en) | Methods and compositions for cryopreserving oocytes | |
| HK40075544A (en) | Cold storage solution for stem cells | |
| FR2846005A1 (fr) | Composition pour milieu biologique comprenant de l'erythorbate de sodium | |
| CN115698263B (zh) | 用于心肌细胞冻存的组合物 | |
| KR101746025B1 (ko) | 아스타잔틴 또는 커큐민을 포함하는 돼지 정자 동결보존용 조성물 | |
| EP1922923A2 (en) | Methods and compositions for cryopreserving oocytes | |
| KR20250097929A (ko) | 줄기세포용 냉장 보존액 | |
| HK40121913A (en) | Cold storage solution for stem cells | |
| US20040101961A1 (en) | Insect cell primary culture medium, extracellular matrix, and process of preparing an insect culture cell line in a short period of time using the medium and matrix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22807260 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023520914 Country of ref document: JP |
|
| ENP | Entry into the national phase |
Ref document number: 20237038212 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020237038212 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202280033722.X Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2022807260 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2022807260 Country of ref document: EP Effective date: 20231211 |
|
| WWP | Wipo information: published in national office |
Ref document number: 18290016 Country of ref document: US |